Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers

NCT03816332 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

12

Enrollment

NIH

Sponsor class

Conditions

Clinical Stage III Cutaneous Melanoma AJCC v8
Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Clinical Stage IV Cutaneous Melanoma AJCC v8
Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
Metastatic Basal Cell Carcinoma
Metastatic Melanoma
Metastatic Merkel Cell Carcinoma
Metastatic Skin Squamous Cell Carcinoma
Pathologic Stage III Cutaneous Melanoma AJCC v8
Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
Pathologic Stage IIIA Cutaneous Melanoma AJCC v8
Pathologic Stage IIIA Cutaneous Merkel Cell Carcinoma AJCC v8
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
Pathologic Stage IIIB Cutaneous Merkel Cell Carcinoma AJCC v8
Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
Pathologic Stage IIID Cutaneous Melanoma AJCC v8
Pathologic Stage IV Cutaneous Melanoma AJCC v8
Pathologic Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
Unresectable Basal Cell Carcinoma
Unresectable Melanoma
Unresectable Merkel Cell Carcinoma

Interventions

BIOLOGICAL: Ipilimumab
BIOLOGICAL: Nivolumab
DRUG: Prednisone
DRUG: Tacrolimus

Sponsor

National Cancer Institute (NCI)